Cellectar BioSciences

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Cellectar BioSciences reports strong Q1 results and eyes FDA submission

Cellectar BioSciences is well-positioned with strong financial backing and promising product developments. Challenges include financial losses, pricing strategy, and market competition. Opportunities lie in upcoming data releases, FDA submission, and global partnerships.

Cellectar BioSciences reports strong Q2 performance and prepares for NDA submission

Cellectar BioSciences showcased strong financial performance and promising trial results in Q2 2024.
While facing challenges in financial restatements and analyst inquiries, the company is progressing well with NDA preparations.
The company's confidence in the NDA filing, supported by robust data, highlights growth opportunities in addressing unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Successful track record of developing and advancing oncology clinical programs through regulatory approval Successful track record of developing and advancing oncology clinical programs through regulatory approval

Cellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief Medical Officer

Cellectar Biosciences Inc (NASDAQ: CLRB) has completed part A portion of a safety and tolerability study of iopofosine I-131 (iopofosine) in combination with external beam radiation (EBRT) in relapsed or refractory head and neck cancer.  Related: Cellectar Receives $2M NIH Grant For Rare Lymphoma Study.

Cellectar Bio's Iopofosine Data Shows Favorable Safety Profile In Head & Neck Cancer

FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that James Caruso, president and CEO, will present a company overview at the following upcoming conference:

Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Cellectar Biosciences Inc (NASDAQ: CLRB) has received a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 million from the National Cancer Institute (NCI). The Company is currently conducting a pivotal study of iopofosine I-131 (CLR 131) in Waldenstrom's macroglobulinemia (WM) patients who have received at least two prior lines of therapy.

Cellectar Receives $2M NIH Grant For Rare Lymphoma Study

FLORHAM PARK, N.J., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced it has been awarded a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 Million from the National Cancer Institute (NCI).

Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom's Macroglobulinemia

Evergreen to provide clinical and commercial supply of iopofosine I-131 (also known as CLR 131)

Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131

FLORHAM PARK, N.J., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update

Preclinical Data Supports Further Development of Multiple Novel Phospholipid Drug Conjugates (PDCs) Preclinical Data Supports Further Development of Multiple Novel Phospholipid Drug Conjugates (PDCs)

Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc.

Cellectar Biosciences Inc (NASDAQ: CLRB) has collaborated with LegoChemBio to develop and commercialize phospholipid drug conjugates (PDCs). Under the agreement, the two companies have the option to jointly develop three new small molecule PDCs utilizing Cellectar's drug targeting platform, phospholipid ether technology, and LegoChemBio's proprietary drug conjugate linker-toxin platform.

Cellectar, LegoChemBio Team Up To Develop Phospholipid Drug Conjugates For Solid Tumors

Development of Multiple Novel PDCs Development of Multiple Novel PDCs

Cellectar Announces a Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phospholipid Drug Conjugates (PDCs)

FLORHAM PARK, N.J., July 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that James Caruso, president and CEO, will present a company overview and be available for 1x1 meetings at the following upcoming conference:

Cellectar to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference

FLORHAM PARK, N.J., June 24, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Dr. Asher Alban Chanan-Khan has been elected to its board of directors as an independent director.

Cellectar Announces the Election of Dr. Asher Alban Chanan-Khan to Its Board of Directors

Cellectar Biosciences Inc (NASDAQ: CLRB) announced updated data at the American Society of Clinical Oncology (ASCO) Annual Meeting from Phase 2 CLOVER-1 study of CLR 131 in relapsed/refractory B-cell hematologic cancers. Data from 131 Waldenstrom's macroglobulinemia (WM) patients showed a 100% (6/6) overall response rate, 83.3% major response rate, and a 16.7% complete response rate.

Cellectar Bio Stock Drops After ASCO Presentation on White Blood Cell Cancer Therapy

Mean treatment free remission 1.1 years and remains ongoing

Cellectar Presents Data in Waldenstrom's Macroglobulinemia in Poster at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Management to host a KOL call with Dr. Sikandar Ailawadhi, M.D., lead investigator on June 4 at 10:00 am Management to host a KOL call with Dr. Sikandar Ailawadhi, M.D., lead investigator on June 4 at 10:00 am

Cellectar Announces Poster Presentation of CLR 131 Data in Waldenstrom's Macroglobulinemia at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

FLORHAM PARK, N.J., May 14, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the company will participate and be available for 1x1 meetings at the following upcoming conference:

Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021

Initiated pivotal study of CLR 131 in Waldenstrom's macroglobulinemia (WM) Received European Orphan Drug Designation for CLR 131 in WM

Cellectar Reports Financial Results for the First Quarter 2021 and Provides a Corporate Update

New patent covers phospholipid-ether analogs combined with various small molecule chemotherapeutics and methods of use for PDCs™ New patent covers phospholipid-ether analogs combined with various small molecule chemotherapeutics and methods of use for PDCs™

Cellectar Strengthens Global IP Position with Phospholipid Drug Conjugate Composition of Matter Patent in Eurasia, Australia, and Mexico

FLORHAM PARK, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and CEO, will present a company overview and be available for 1x1 meetings at the following upcoming conferences:

Cellectar to Participate at Upcoming Institutional Investor Conferences

FLORHAM PARK, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and CEO will present a company overview at the virtual 2021 BIO CEO & Investor Digital Conference to be held from February 16-18, 2021.

Cellectar to Present at BIO CEO & Investor Digital Conference

Benefits include 10 years of market exclusivity in the European Union Benefits include 10 years of market exclusivity in the European Union

Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom's Macroglobulinemia

FLORHAM PARK, N.J., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of its common stock for gross proceeds of approximately $24.5 million at a public offering price of $1.35 per share of common stock, prior to deducting underwriting discounts and commissions and estimated offering expenses.

Cellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement

FLORHAM PARK, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the pricing of its previously announced underwritten public offering of its common stock for gross proceeds of approximately $24.5 million at a public offering price of $1.35 per share of common stock, prior to deducting underwriting discounts and commissions and estimated offering expenses.

Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement

FLORHAM PARK, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it intends to offer and sell shares of its common stock and common stock equivalents in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Cellectar Biosciences Announces Proposed Underwritten Public Offering and Concurrent Private Placement

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 817 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are collectively bullish on. One of their picks is Cellectar Biosciences, Inc. (NASDAQ:CLRB), so let's take a closer look at the sentiment that surrounds it in the current quarter.

News for Cellectar BioSciences Stock (CLRB)